国: アメリカ合衆国
言語: 英語
ソース: NLM (National Library of Medicine)
ESTRADIOL CYPIONATE (UNII: 7E1DV054LO) (ESTRADIOL CYPIONATE - UNII:7E1DV054LO)
Physicians Total Care, Inc.
ESTRADIOL CYPIONATE
ESTRADIOL CYPIONATE 5 mg in 1 mL
INTRAMUSCULAR
PRESCRIPTION DRUG
DEPO-Estradiol Injection is indicated in the treatment of: - Moderate to severe vasomotor symptoms associated with the menopause. - Hypoestrogenism due to hypogonadism. Estrogens should not be used in individuals with any of the following conditions: - Undiagnosed abnormal genital bleeding. - Known or suspected cancer of the breast. - Known or suspected estrogen-dependent neoplasia. - Active deep vein thrombosis, pulmonary embolism or history of these conditions. - Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - Liver dysfunction or disease. - DEPO-Estradiol should not be used in patients with known hypersensitivity to its ingredients. - Known or suspected pregnancy. There is no indication for DEPO-Estradiol in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See PRECAUTIONS.) Chlorobu
DEPO-Estradiol Injection is available in the following concentration containing per mL: 5 mg estradiol cypionate; also 5.4 mg chlorobutanol anhydrous (chloral deriv.) added as preservative; in 913 mg cottonseed oil— in 5 mL vials, NDC 54868-1729-0. WARNING: Chlorobutanol may be habit forming. Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].
Abbreviated New Drug Application
DEPO-ESTRADIOL - ESTRADIOL CYPIONATE INJECTION PHYSICIANS TOTAL CARE, INC. ---------- DEPO -ESTRADIOL ESTRADIOL CYPIONATE INJECTION, USP WARNINGS ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures including endometrial sampling, when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is currently no evidence that the use of "natural" estrogens results in a different endometrial risk profile than "synthetic" estrogens at equivalent estrogen doses. (SEE WARNINGS, MALIGNANT NEOPLASMS, ENDOMETRIAL CANCER.) CARDIOVASCULAR AND OTHER RISKS Estrogens with and without progestins should not be used for the prevention of cardiovascular disease. (SEE WARNINGS, CARDIOVASCULAR DISORDERS.) The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES.) The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES.) Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or 完全なドキュメントを読む